Pre-made Acasunlimab benchmark antibody ( Bispecific mAb, anti-CD274/PD-L1;TNFRSF9/CD137 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Acasunlimab benchmark antibody (Bispecific mAb, anti-CD274/PD-L1;TNFRSF9/CD137 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Acasunlimab biosimilar, Bispecific mAb, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 Antibod: Anti-CD274/PD-L1;TNFRSF9/CD137 therapeutic antibody |
|---|---|
| INN Name | Acasunlimab |
| Target | CD274,TNFRSF9 |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2020 |
| Year Recommended | NA |
| Companies | Genmab,BioNTech |
| Conditions Approved | NA |
| Conditions Active | Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | DuoBody |
| Previous Name | NA |
| Gm Offical Target Name | CD274/PD-L1,TNFRSF9/CD137 |
| Package |
